Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models

Journal of Chemical Information and Modeling

Volumn 55, Issue 8, 2015, Pages 1720-1738

  Ha, Helen ^a   Debnath, Bikash ^b   Odde, Srinivas ^a   Bensman, Tim ^a   Ho, Henry ^a   Beringer, Paul M ^a   Neamati, Nouri ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDES; BIOLOGICAL ORGANS; CELL PROLIFERATION; CELLS; CYTOLOGY; DIAGNOSIS; LIGANDS; MAMMALS; MOLECULES; PATHOLOGY; PULMONARY DISEASES; SULFUR COMPOUNDS;

ANTI-INFLAMMATORY AGENTS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; NEUTROPHIL MIGRATION; PHARMACEUTICAL COMPANY; PHARMACOPHORE MODELING; PHARMACOPHORE MODELS; SMALL MOLECULE INHIBITOR;

PHARMACODYNAMICS;

ANTIINFLAMMATORY AGENT; BETA ARRESTIN; CHEMOKINE RECEPTOR CXCR2; RETINA S ANTIGEN; SULFONAMIDE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; HUMAN; IMMUNOLOGY; INFLAMMATION; LUNG; MALE; MOUSE; TUMOR CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARRESTINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHO CELLS; CRICETULUS; HUMANS; INFLAMMATION; LUNG; MALE; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; RECEPTORS, INTERLEUKIN-8B; SULFONAMIDES;

EID: 84940213352     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/acs.jcim.5b00181     Document Type: Article

References (74)

1. Baggiolini, M.; Dewald, B.; Moser, B. Interleukin-8 and Related Chemotactic Cytokines - CXC and CC Chemokines Adv. Immunol. 1994, 55, 97-179 10.1016/S0065-2776(08)60509-X
2. Xu, L.; Kelvin, D. J.; Ye, G. Q.; Taub, D. D.; Ben-Baruch, A.; Oppenheim, J. J.; Wang, J. M. Modulation of Il-8 Receptor Expression on Purified Human T Lymphocytes Is Associated with Changed Chemotactic Responses to Il-8 J. Leukocyte Biol. 1995, 57, 335-342
3. Chuntharapai, A.; Lee, J.; Hebert, C. A.; Kim, K. J. Monoclonal Antibodies Detect Different Distribution Patterns of Il-8 Receptor a and Il-8 Receptor B on Human Peripheral Blood Leukocytes J. Immunol. 1994, 153, 5682-5688
4. Murdoch, C.; Monk, P. N.; Finn, A. CXC Chemokine Receptor Expression on Human Endothelial Cells Cytokine+ 1999, 11, 704-712 10.1006/cyto.1998.0465
5. Horuk, R.; Martin, A. W.; Wang, Z.; Schweitzer, L.; Gerassimides, A.; Guo, H.; Lu, Z.; Hesselgesser, J.; Perez, H. D.; Kim, J.; Parker, J.; Hadley, T. J.; Peiper, S. C. Expression of Chemokine Receptors by Subsets of Neurons in the Central Nervous System J. Immunol. 1997, 158, 2882-2890
6. Ahuja, S. K.; Murphy, P. M. The CXC Chemokines Growth-Regulated Oncogene (Gro) Alpha, Grobeta, Grogamma, Neutrophil-Activating Peptide-2, and Epithelial Cell-Derived Neutrophil-Activating Peptide-78 Are Potent Agonists for the Type B, but Not the Type a, Human Interleukin-8 Receptor J. Biol. Chem. 1996, 271, 20545-20550 10.1074/jbc.271.34.20545
7. Murphy, P. M.; Tiffany, H. L. Cloning of Complementary DNA Encoding a Functional Human Interleukin-8 Receptor Science 1991, 253, 1280-1283 10.1126/science.1891716
8. Coffer, J. P.; Geijsen, N.; M'Rabet, L.; Schweizer, C. R.; Maikoe, T.; Raaijmakers, A. M. J.; Lammers, J.-W. J.; Koenderman, L. Comparison of the Roles of Mitogen-Activated Protein Kinase Kinase and Phosphatidylinositol 3-Kinase Signal Transduction in Neutrophil Effector Function Biochem. J. 1998, 329, 121-130 10.1042/bj3290121
9. Constantin, G.; Majeed, M.; Giagulli, C.; Piccio, L.; Kim, J. Y.; Butcher, E. C.; Laudanna, C. Chemokines Trigger Immediate Beta2 Integrin Affinity and Mobility Changes: Differential Regulation and Roles in Lymphocyte Arrest under Flow Immunity 2000, 13, 759-769 10.1016/S1074-7613(00)00074-1
10. Addison, C. L.; Daniel, T. O.; Burdick, M. D.; Liu, H.; Ehlert, J. E.; Xue, Y. Y.; Buechi, L.; Walz, A.; Richmond, A.; Strieter, R. M. The CXC Chemokine Receptor 2, CXCR2, Is the Putative Receptor for Elr+ CXC Chemokine-Induced Angiogenic Activity J. Immunol. 2000, 165, 5269-5277 10.4049/jimmunol.165.9.5269
11. Nocker, R. E.; Schoonbrood, D. F.; van de Graaf, E. A.; Hack, C. E.; Lutter, R.; Jansen, H. M.; Out, T. A. Interleukin-8 in Airway Inflammation in Patients with Asthma and Chronic Obstructive Pulmonary Disease Int. Arch. Allergy Immunol. 1996, 109, 183-191 10.1159/000237218
12. Yamamoto, C.; Yoneda, T.; Yoshikawa, M.; Fu, A.; Tokuyama, T.; Tsukaguchi, K.; Narita, N. Airway Inflammation in Copd Assessed by Sputum Levels of Interleukin-8 Chest 1997, 112, 505-510 10.1378/chest.112.2.505
13. Busch-Petersen, J. Small Molecule Antagonists of the CXCR2 and CXCR1 Chemokine Receptors as Therapeutic Agents for the Treatment of Inflammatory Diseases Curr. Top. Med. Chem. 2006, 6, 1345-1352 10.2174/15680266106061345
14. Widdowson, K. L. Phenyl Urea Interleukin-8 Receptor Antagonists for Treatment of Interleukin-8-Mediated Diseases, and Preparation Thereof. WO199749286, 1997.
15. Zhu, Y. M.; Webster, S. J.; Flower, D.; Woll, P. J. Interleukin-8/CXCL8 Is a Growth Factor for Human Lung Cancer Cells Br. J. Cancer 2004, 91, 1970-1976 10.1038/sj.bjc.6602227
16. Rubie, C.; Kollmar, O.; Frick, V. O.; Wagner, M.; Brittner, B.; Graber, S.; Schilling, M. K. Differential CXC Receptor Expression in Colorectal Carcinomas Scand. J. Immunol. 2008, 68, 635-644 10.1111/j.1365-3083.2008.02163.x
17. Murphy, C.; McGurk, M.; Pettigrew, J.; Santinelli, A.; Mazzucchelli, R.; Johnston, P. G.; Montironi, R.; Waugh, D. J. Nonapical and Cytoplasmic Expression of Interleukin-8, CXCR1, and CXCR2 Correlates with Cell Proliferation and Microvessel Density in Prostate Cancer Clin. Cancer Res. 2005, 11, 4117-4127 10.1158/1078-0432.CCR-04-1518
18. Yang, G.; Rosen, D. G.; Liu, G.; Yang, F.; Guo, X.; Xiao, X.; Xue, F.; Mercado-Uribe, I.; Huang, J.; Lin, S. H.; Mills, G. B.; Liu, J. CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis Clin. Cancer Res. 2010, 16, 3875-3886 10.1158/1078-0432.CCR-10-0483
19. Luppi, F.; Longo, A. M.; de Boer, W. I.; Rabe, K. F.; Hiemstra, P. S. Interleukin-8 Stimulates Cell Proliferation in Non-Small Cell Lung Cancer through Epidermal Growth Factor Receptor Transactivation Lung Cancer 2007, 56, 25-33 10.1016/j.lungcan.2006.11.014
20. Ning, Y.; Manegold, P. C.; Hong, Y. K.; Zhang, W.; Pohl, A.; Lurje, G.; Winder, T.; Yang, D.; LaBonte, M. J.; Wilson, P. M.; Ladner, R. D.; Lenz, H. J. Interleukin-8 Is Associated with Proliferation, Migration, Angiogenesis and Chemosensitivity in Vitro and in Vivo in Colon Cancer Cell Line Models Int. J. Cancer 2011, 128, 2038-2049 10.1002/ijc.25562
21. Waugh, D. J.; Wilson, C. The Interleukin-8 Pathway in Cancer Clin. Cancer Res. 2008, 14, 6735-6741 10.1158/1078-0432.CCR-07-4843
22. Li, A.; Varney, M. L.; Singh, R. K. Constitutive Expression of Growth Regulated Oncogene (Gro) in Human Colon Carcinoma Cells with Different Metastatic Potential and Its Role in Regulating Their Metastatic Phenotype Clin. Exp. Metastasis 2005, 21, 571-579 10.1007/s10585-004-5458-3
23. Ogata, H.; Sekikawa, A.; Yamagishi, H.; Ichikawa, K.; Tomita, S.; Imura, J.; Ito, Y.; Fujita, M.; Tsubaki, M.; Kato, H.; Fujimori, T.; Fukui, H. GROα Promotes Invasion of Colorectal Cancer Cells Oncol. Rep. 2010, 24, 1479-1486 10.3892/or-00001008
24. Keane, M. P.; Belperio, J. A.; Xue, Y. Y.; Burdick, M. D.; Strieter, R. M. Depletion of CXCR2 Inhibits Tumor Growth and Angiogenesis in a Murine Model of Lung Cancer J. Immunol. 2004, 172, 2853-2860 10.4049/jimmunol.172.5.2853
25. Catalyst, version 4.11; Accelrys, Inc.: San Diego, CA, 2005; http://www.accelrys.com.
26. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking J. Mol. Biol. 1997, 267, 727-748 10.1006/jmbi.1996.0897
27. Jones, G.; Willett, P.; Glen, R. C. Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation J. Mol. Biol. 1995, 245, 43-53 10.1016/S0022-2836(95)80037-9
28. ROCS, version 3.2.0.4; OpenEye Scientific Software: Santa Fe, NM; http://www.eyesopen.com.
29. Hawkins, P. C.; Skillman, A. G.; Nicholls, A. Comparison of Shape-Matching and Docking as Virtual Screening Tools J. Med. Chem. 2007, 50, 74-82 10.1021/jm0603365
30. Dwyer, M. P.; Yu, Y.; Chao, J.; Aki, C.; Chao, J.; Biju, P.; Girijavallabhan, V.; Rindgen, D.; Bond, R.; Mayer-Ezel, R.; Jakway, J.; Hipkin, R. W.; Fossetta, J.; Gonsiorek, W.; Bian, H.; Fan, X.; Terminelli, C.; Fine, J.; Lundell, D.; Merritt, J. R.; Rokosz, L. L.; Kaiser, B.; Li, G.; Wang, W.; Stauffer, T.; Ozgur, L.; Baldwin, J.; Taveras, A. G. Discovery of 2-Hydroxy-N,N-Dimethyl-3-{2-[[(R)-1-(5- Methylfuran-2-Yl)Propyl]Amino]-3,4-Dioxocyclobut-1-Enylamino}Benzamide (Sch 527123): A Potent, Orally Bioavailable CXCR2/CXCR1 Receptor Antagonist J. Med. Chem. 2006, 49, 7603-7606 10.1021/jm0609622
31. Jin, Q.; Nie, H.; McCleland, B. W.; Widdowson, K. L.; Palovich, M. R.; Elliott, J. D.; Goodman, R. M.; Burman, M.; Sarau, H. M.; Ward, K. W.; Nord, M.; Orr, B. M.; Gorycki, P. D.; Busch-Petersen, J. Discovery of Potent and Orally Bioavailable N,N′-Diarylurea Antagonists for the CXCR2 Chemokine Receptor Bioorg. Med. Chem. Lett. 2004, 14, 4375-4378 10.1016/j.bmcl.2004.06.097
32. McCleland, B. W.; Davis, R. S.; Palovich, M. R.; Widdowson, K. L.; Werner, M. L.; Burman, M.; Foley, J. J.; Schmidt, D. B.; Sarau, H. M.; Rogers, M.; Salyers, K. L.; Gorycki, P. D.; Roethke, T. J.; Stelman, G. J.; Azzarano, L. M.; Ward, K. W.; Busch-Petersen, J. Comparison of N,N′-Diarylsquaramides and N,N′-Diarylureas as Antagonists of the CXCR2 Chemokine Receptor Bioorg. Med. Chem. Lett. 2007, 17, 1713-1717 10.1016/j.bmcl.2006.12.067
33. Merritt, J. R.; Rokosz, L. L.; Nelson, K. H., Jr.; Kaiser, B.; Wang, W.; Stauffer, T. M.; Ozgur, L. E.; Schilling, A.; Li, G.; Baldwin, J. J.; Taveras, A. G.; Dwyer, M. P.; Chao, J. Synthesis and Structure-Activity Relationships of 3,4-Diaminocyclobut-3-Ene-1,2-Dione CXCR2 Antagonists Bioorg. Med. Chem. Lett. 2006, 16, 4107-4110 10.1016/j.bmcl.2006.04.082
34. Nie, H.; Widdowson, K. L.; Palovich, M. R.; Fu, W.; Elliott, J. D.; Bryan, D. L.; Burman, M.; Schmidt, D. B.; Foley, J. J.; Sarau, H. M.; Busch-Petersen, J. N,N′-Diarylcyanoguanidines as Antagonists of the CXCR2 and CXCR1 Chemokine Receptors Bioorg. Med. Chem. Lett. 2006, 16, 5513-5516 10.1016/j.bmcl.2006.08.042
35. Widdowson, K. L.; Elliott, J. D.; Veber, D. F.; Nie, H.; Rutledge, M. C.; McCleland, B. W.; Xiang, J. N.; Jurewicz, A. J.; Hertzberg, R. P.; Foley, J. J.; Griswold, D. E.; Martin, L.; Lee, J. M.; White, J. R.; Sarau, H. M. Evaluation of Potent and Selective Small-Molecule Antagonists for the CXCR2 Chemokine Receptor J. Med. Chem. 2004, 47, 1319-1321 10.1021/jm034248l
36. Discovery Studio 2.0; Accelrys, Inc.: San Diego, CA, 2009; http://www.accelrys.com.
37. Smellie, A.; Teig, S. L.; Towbin, P. Poling: Promoting Conformational Coverage J. Comput. Chem. 1995, 16, 171-187 10.1002/jcc.540160205
38. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of Conformational Coverage. 1. Validation and Estimation of Coverage J. Chem. Inf. Model. 1995, 35, 285-294 10.1021/ci00024a018
39. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of Conformational Coverage. 2. Applications of Conformational Models J. Chem. Inf. Model. 1995, 35, 295-304 10.1021/ci00024a019
40. Güner, O. F.; Henry, D. R. Metric for Analyzing Hit Lists and Pharmacophores. In Pharmacophore Perception, Development, and Use in Drug Design; Güner, O. F., Ed.; International University Line: La Jolla, CA, 2000; Chapter 11, pp 193-212.
41. Aki, C.; Chao, J.; Ferreira, J. A.; Dwyer, M. P.; Yu, Y.; Chao, J.; Merritt, R. J.; Lai, G.; Wu, M.; Hipkin, R. W.; Fan, X.; Gonsiorek, W.; Fosseta, J.; Rindgen, D.; Fine, J.; Lundell, D.; Taveras, A. G.; Biju, P. Diaminocyclobutenediones as Potent and Orally Bioavailable CXCR2 Receptor Antagonists: Sar in the Phenolic Amide Region Bioorg. Med. Chem. Lett. 2009, 19, 4446-4449 10.1016/j.bmcl.2009.05.049
42. Biju, P.; Taveras, A. G.; Dwyer, M. P.; Yu, Y.; Chao, J.; Hipkin, R. W.; Fan, X.; Rindgen, D.; Fine, J.; Lundell, D. Fluoroalkyl Alpha Side Chain Containing 3,4-Diamino-Cyclobutenediones as Potent and Orally Bioavailable CXCR2-CXCR1 Dual Antagonists Bioorg. Med. Chem. Lett. 2009, 19, 1431-1433 10.1016/j.bmcl.2009.01.033
43. Chao, J.; Taveras, A. G.; Chao, J.; Aki, C.; Dwyer, M.; Yu, Y.; Purakkattle, B.; Rindgen, D.; Jakway, J.; Hipkin, W.; Fosetta, J.; Fan, X.; Lundell, D.; Fine, J.; Minnicozzi, M.; Phillips, J.; Merritt, J. R. C(4)-Alkyl Substituted Furanyl Cyclobutenediones as Potent, Orally Bioavailable CXCR2 and CXCR1 Receptor Antagonists Bioorg. Med. Chem. Lett. 2007, 17, 3778-3783 10.1016/j.bmcl.2007.04.016
44. Baxter, A.; Bennion, C.; Bent, J.; Boden, K.; Brough, S.; Cooper, A.; Kinchin, E.; Kindon, N.; McInally, T.; Mortimore, M.; Roberts, B.; Unitt, J. Hit-to-Lead Studies: The Discovery of Potent, Orally Bioavailable Triazolethiol CXCR2 Receptor Antagonists Bioorg. Med. Chem. Lett. 2003, 13, 2625-2628 10.1016/S0960-894X(03)00561-4
45. Hunt, F.; Austin, C.; Austin, R.; Bonnert, R.; Cage, P.; Christie, J.; Christie, M.; Dixon, C.; Hill, S.; Jewell, R.; Martin, I.; Robinson, D.; Willis, P. Sar Studies on Thiazolo[4,5-D]Pyrimidine Based CXCR2 Antagonists Involving a Novel Tandem Displacement Reaction Bioorg. Med. Chem. Lett. 2007, 17, 2731-2734 10.1016/j.bmcl.2007.02.080
46. Porter, D. W.; Bradley, M.; Brown, Z.; Canova, R.; Charlton, S.; Cox, B.; Hunt, P.; Kolarik, D.; Lewis, S.; O'Connor, D.; Reilly, J.; Spanka, C.; Tedaldi, L.; Watson, S. J.; Wermuth, R.; Press, N. J. The Discovery of Potent, Orally Bioavailable Pyrazolo and Triazolopyrimidine CXCR2 Receptor Antagonists Bioorg. Med. Chem. Lett. 2014, 24, 72-76 10.1016/j.bmcl.2013.11.074
47. Walters, I.; Austin, C.; Austin, R.; Bonnert, R.; Cage, P.; Christie, M.; Ebden, M.; Gardiner, S.; Grahames, C.; Hill, S.; Hunt, F.; Jewell, R.; Lewis, S.; Martin, I.; Nicholls, D.; Robinson, D. Evaluation of a Series of Bicyclic CXCR2 Antagonists Bioorg. Med. Chem. Lett. 2008, 18, 798-803 10.1016/j.bmcl.2007.11.039
48. Wang, Y.; Busch-Petersen, J.; Wang, F.; Ma, L.; Fu, W.; Kerns, J. K.; Jin, J.; Palovich, M. R.; Shen, J. K.; Burman, M.; Foley, J. J.; Schmidt, D. B.; Hunsberger, G. E.; Sarau, H. M.; Widdowson, K. L. 3-Arylamino-2h-1,2,4-Benzothiadiazin-5-Ol 1,1-Dioxides as Novel and Selective CXCR2 Antagonists Bioorg. Med. Chem. Lett. 2007, 17, 3864-3867 10.1016/j.bmcl.2007.05.011
49. Winters, M. P.; Crysler, C.; Subasinghe, N.; Ryan, D.; Leong, L.; Zhao, S.; Donatelli, R.; Yurkow, E.; Mazzulla, M.; Boczon, L.; Manthey, C. L.; Molloy, C.; Raymond, H.; Murray, L.; McAlonan, L.; Tomczuk, B. Carboxylic Acid Bioisosteres Acylsulfonamides, Acylsulfamides, and Sulfonylureas as Novel Antagonists of the CXCR2 Receptor Bioorg. Med. Chem. Lett. 2008, 18, 1926-1930 10.1016/j.bmcl.2008.01.127
50. Yu, Y.; Dwyer, M. P.; Chao, J.; Aki, C.; Chao, J.; Purakkattle, B.; Rindgen, D.; Bond, R.; Mayer-Ezel, R.; Jakway, J.; Qiu, H.; Hipkin, R. W.; Fossetta, J.; Gonsiorek, W.; Bian, H.; Fan, X.; Terminelli, C.; Fine, J.; Lundell, D.; Merritt, J. R.; He, Z.; Lai, G.; Wu, M.; Taveras, A. Synthesis and Structure-Activity Relationships of Heteroaryl Substituted-3,4-Diamino-3-Cyclobut-3-Ene-1,2-Dione CXCR2/CXCR1 Receptor Antagonists Bioorg. Med. Chem. Lett. 2008, 18, 1318-1322 10.1016/j.bmcl.2008.01.024
51. Cutshall, N. S.; Ursino, R.; Kucera, K. A.; Latham, J.; Ihle, N. C. Nicotinamide N-Oxides as CXCR2 Antagonists Bioorg. Med. Chem. Lett. 2001, 11, 1951-1954 10.1016/S0960-894X(01)00326-2
52. Liu, S.; Liu, Y.; Wang, H.; Ding, Y.; Wu, H.; Dong, J.; Wong, A.; Chen, S. H.; Li, G.; Chan, M.; Sawyer, N.; Gervais, F. G.; Henault, M.; Kargman, S.; Bedard, L. L.; Han, Y.; Friesen, R.; Lobell, R. B.; Stout, D. M. Design, Synthesis, and Evaluation of Novel 3-Amino-4-Hydrazine-Cyclobut-3-Ene-1,2-Diones as Potent and Selective CXCR2 Chemokine Receptor Antagonists Bioorg. Med. Chem. Lett. 2009, 19, 5741-5745 10.1016/j.bmcl.2009.08.014
53. Lu, H.; Yang, T.; Xu, Z.; Wren, P. B.; Zhang, Y.; Cai, X.; Patel, M.; Dong, K.; Zhang, Q.; Zhang, W.; Guan, X.; Xiang, J.; Elliott, J. D.; Lin, X.; Ren, F. 2-Aminopyrimidin-4(1h)-One as the Novel Bioisostere of Urea: Discovery of Novel and Potent CXCR2 Antagonists Bioorg. Med. Chem. Lett. 2014, 24, 5493-5496 10.1016/j.bmcl.2014.10.003
54. Maeda, D. Y.; Peck, A. M.; Schuler, A. D.; Quinn, M. T.; Kirpotina, L. N.; Wicomb, W. N.; Fan, G. H.; Zebala, J. A. Discovery of 2-[5-(4-Fluorophenylcarbamoyl)Pyridin-2-Ylsulfanylmethyl]Phenylboronic Acid (Sx-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2 J. Med. Chem. 2014, 57, 8378-8397 10.1021/jm500827t
55. Porter, D. W.; Bradley, M.; Brown, Z.; Charlton, S. J.; Cox, B.; Hunt, P.; Janus, D.; Lewis, S.; Oakley, P.; O'Connor, D.; Reilly, J.; Smith, N.; Press, N. J. The Discovery of Potent, Orally Bioavailable Pyrimidine-5-Carbonitrile-6-Alkyl CXCR2 Receptor Antagonists Bioorg. Med. Chem. Lett. 2014, 24, 3285-3290 10.1016/j.bmcl.2014.06.011
56. Isberg, V.; Vroling, B.; van der Kant, R.; Li, K.; Vriend, G.; Gloriam, D. Gpcrdb: An Information System for G Protein-Coupled Receptors Nucleic Acids Res. 2014, 42, D422-425 10.1093/nar/gkt1255
57. Fiser, A.; Sali, A. Modloop: Automated Modeling of Loops in Protein Structures Bioinformatics 2003, 19, 2500-2501 10.1093/bioinformatics/btg362
58. Hawkins, P. C.; Skillman, A. G.; Warren, G. L.; Ellingson, B. A.; Stahl, M. T. Conformer Generation with Omega: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database J. Chem. Inf. Model. 2010, 50, 572-584 10.1021/ci100031x
59. Altenburg, J. D.; Broxmeyer, H. E.; Jin, Q.; Cooper, S.; Basu, S.; Alkhatib, G. A Naturally Occurring Splice Variant of Cxcl12/Stromal Cell-Derived Factor 1 Is a Potent Human Immunodeficiency Virus Type 1 Inhibitor with Weak Chemotaxis and Cell Survival Activities J. Virol. 2007, 81, 8140-8148 10.1128/JVI.00268-07
60. Carmichael, J.; DeGraff, W. G.; Gazdar, A. F.; Minna, J. D.; Mitchell, J. B. Evaluation of a Tetrazolium-Based Semiautomated Colorimetric Assay: Assessment of Chemosensitivity Testing Cancer Res. 1987, 47, 936-942
61. Kilkenny, C.; Browne, W. J.; Cuthill, I. C.; Emerson, M.; Altman, D. G. Improving Bioscience Research Reporting: The Arrive Guidelines for Reporting Animal Research PLoS Biol. 2010, 8, e1000412 10.1371/journal.pbio.1000412
62. McGrath, J. C.; Drummond, G. B.; McLachlan, E. M.; Kilkenny, C.; Wainwright, C. L. Guidelines for Reporting Experiments Involving Animals: The Arrive Guidelines Br. J. Pharmacol. 2010, 160, 1573-1576 10.1111/j.1476-5381.2010.00873.x
63. Dayam, R.; Aiello, F.; Deng, J.; Wu, Y.; Garofalo, A.; Chen, X.; Neamati, N. Discovery of Small Molecule Integrin Alphavbeta3 Antagonists as Novel Anticancer Agents J. Med. Chem. 2006, 49, 4526-4534 10.1021/jm051296s
64. Pharmacophore Perception, Development, and Use in Drug Design; Güner, O. F., Ed.; International University Line: La Jolla, CA, 2000.
65. Vitas-M Laboratory Screening Compounds. www.vitasmlab.com.
66. Enamine Screening Collection. http://www.enamine.net/.
67. Asinex Libraries. www.asinex.com.
68. de Kruijf, P.; van Heteren, J.; Lim, H. D.; Conti, P. G. M.; van der Lee, M. M. C.; Bosch, L.; Ho, K.-K.; Auld, D.; Ohlmeyer, M.; Smit, M. J.; Wijkmans, J. C. H. M.; Zaman, G. J. R.; Smit, M. J.; Leurs, R. Nonpeptidergic Allosteric Antagonists Differentially Bind to the CXCR2 Chemokine Receptor J. Pharmacol. Exp. Ther. 2009, 329, 783-790 10.1124/jpet.108.148387
69. Salchow, K.; Bond, M. E.; Evans, S. C.; Press, N. J.; Charlton, S. J.; Hunt, P. A.; Bradley, M. E. A Common Intracellular Allosteric Binding Site for Antagonists of the CXCR2 Receptor Br. J. Pharmacol. 2010, 159, 1429-1439 10.1111/j.1476-5381.2009.00623.x
70. Singh, S.; Sadanandam, A.; Varney, M. L.; Nannuru, K. C.; Singh, R. K. Small Interfering Rna-Mediated CXCR1 or CXCR2 Knock-Down Inhibits Melanoma Tumor Growth and Invasion Int. J. Cancer 2010, 126, 328-336 10.1002/ijc.24714
71. Goda, A. E.; Koyama, M.; Sowa, Y.; Elokely, K. M.; Yoshida, T.; Kim, B. Y.; Sakai, T. Molecular Mechanisms of the Antitumor Activity of Sb225002: A Novel Microtubule Inhibitor Biochem. Pharmacol. 2013, 85, 1741-1752 10.1016/j.bcp.2013.04.011
72. Du, M.; Qiu, Q.; Gruslin, A.; Gordon, J.; He, M.; Chan, C. C.; Li, D.; Tsang, B. K. Sb225002 Promotes Mitotic Catastrophe in Chemo-Sensitive and -Resistant Ovarian Cancer Cells Independent of P53 Status in Vitro PLoS One 2013, 8, e54572 10.1371/journal.pone.0054572
73. Palm, K.; Luthman, K.; Ungell, A. L.; Strandlund, G.; Artursson, P. Correlation of Drug Absorption with Molecular Surface Properties J. Pharm. Sci. 1996, 85, 32-39 10.1021/js950285r
74. 2+-ATPase Inhibitor Thapsigargin Exp. Cell Res. 1994, 212, 84-92 10.1006/excr.1994.1121